Retension Pharmaceuticals, Inc. (RTSN)
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Retension Pharmaceuticals Inc.
No financial data available.
No debt & equity data available.
No splits on record
Nothing in RTSN's public trading history: no forward or reverse split has affected the share count.
No balance sheet details available.
No income statement data available.
No balance sheet data available.
No cash flow data available.